BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis-Reference-Cited by-同舟云学术

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

Published:2015-10 Issue:10 Volume:26 Page:2092-2097
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Cremolini C.,Di Bartolomeo M.,Amatu A.,Antoniotti C.,Moretto R.,Berenato R.,Perrone F.,Tamborini E.,Aprile G.,Lonardi S.,Sartore-Bianchi A.,Fontanini G.,Milione M.,Lauricella C.,Siena S.,Falcone A.,de Braud F.,Loupakis F.,Pietrantonio F.

Funder

ARCO Foundation and Fondazione IRCCS Istituto Nazionale dei Tumori's

Terapia Molecolare dei Tumori from Fondazione Oncologia Niguarda Ca’ Granda Onlus

EC 7th Framework Colon Therapy Research COLTHERES

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/26/10/2092/16703071/mdv290.pdf

Reference26 articles.

1. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial;Richman;J Clin Oncol,2009

2. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial;Heinemann;Lancet Oncol,2014

3. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer;Douillard;N Engl J Med,2013

4. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer;Tran;Cancer,2011

5. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation;Tie;Int J Cancer,2011

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tretinoin synergistically enhances the antitumor effect of combined BRAF, MEK, and EGFR inhibition in BRAF^V600E colorectal cancer;Cancer Science;2024-08-22

2. The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review;Cancers;2024-08-21

3. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

4. BRAF K601E-mutated metastatic colorectal cancer in response to combination therapy with encorafenib, binimetinib, and cetuximab: A case report;World Journal of Gastrointestinal Oncology;2024-07-15

5. Mucin phenotype and genetic alterations in non-V600E BRAF-mutated colorectal cancer;Human Pathology;2024-03